An observational study in Contraception, sponsored by Bayer. Completed at 19 sites in 8 countries. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-29.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Personal Satisfaction with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Personal Satisfaction · United States.
Among the 91 studies in Personal Satisfaction with a site in United States, this one is the 2nd largest by enrollment of the 11 observational ones that give a count, is one of 7 that started in 2017, is one of 11 observational ones, and was the 41st registered.
543 studies on the registry are indexed under Personal Satisfaction; 91 are open to participants now.
Browse Personal Satisfaction studies →6 of the 91 studies in Personal Satisfaction with a site in United States are open now. Recruiting first, the newest first:
Avant Health LLC · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 8–18
Belmont University · Sites in United States
Ages 18+ · Healthy volunteers
Indiana University · Sites in United States
Ages 18+
Oregon Research Behavioral Intervention Strategies, Inc. · Sites in United States
Ages 3–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Personal Satisfaction studies recruiting now, 18 (47%) set no upper age limit and 15 (39%) stop at 75 or younger; 8 take children under 18; 20 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,134 is above the median of 180 across 115 observational studies indexed under Personal Satisfaction.
Median enrollment 117 across the 80 interventional studies, 83 across the 11 observational. Of the 75 that completed or were terminated, 20 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 91 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 4 studies filed under Personal Satisfaction — fewer than ten, so there is no comparison to draw.
3 of the studies in Personal Satisfaction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110729University of Colorado, DenverQuality of Life and Life Satisfaction in Pediatric and Adolescent Gymnasts Through Injury | 2026-11 |
| NCT06992544Brigham and Women's HospitalTrial of Pistachio Consumption in Older Adults | 2027-03 |
| NCT07228299Indiana UniversitySupporting Families in the ICU | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 91 studies in Personal Satisfaction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this non-interventional study (NIS) is to evaluate user satisfaction with Kyleena in a real-life setting and to identify factors which influence user satisfaction, taking into account previously used contraceptive methods and reasons for use of Kyleena.
Women in the respective participating country requesting contraception with Kyleena will be eligible to be enrolled.
Women can be screened for the study only after an informed decision for Kyleena has been made by the woman and the treating health care professional such as her physician/gynecologist or midwife. Indication and contraindications according to the local market authorization/ summary of product characteristics (SmPC) should be carefully considered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
Drug: Kyleena
Kyleena - intrauterine delivery system containing 19.5 mg LNG
Overall satisfaction with Kyleena assessed by questionnaire
The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).
Time frame: approximately at 12 months after insertion or at premature discontinuation
Overall satisfaction with Kyleena assessed by questionnaire
The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).
Time frame: approximately 4-12 weeks after insertion
Ease of insertion assessed by investigator
The rating is based on the categories easy, slightly difficult, very difficult.
Time frame: Day 1
Pain at insertion assessed by participant
The rating is based on the categories none, mild, moderate, or severe
Time frame: Day 1
Satisfaction with the menstrual bleeding profile with Kyleena assessed by questionnaire
Satisfaction with the menstrual bleeding profile with Kyleena assessed by women who did and did not experience menstrual bleeding during the last three months when answering the question "How satisfied were you with your menstrual bleeding pattern?" respectively. The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).
Time frame: after approximately 12 months or at premature discontinuation and approximately 4-12 weeks after insertion
Ran from Jul 2017 to primary completion in Dec 2019, 29 months.
Of 44 observational studies under Personal Satisfaction, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.